Abstract

Nuclear factor-B (NF-B)/Rel transcription factors have been suspected since their discovery to play a pivotal role in chronic and acute inflammatory diseases. It now seems that aberrant regulation of NF-B could also underlie autoimmune diseases and different types of cancer. Recently, NF-B and the signalling pathways that regulate its activity have become a focal point for intense drug discovery and development efforts. Given the large number of major ailments in which aberrant regulation of NF-B has been observed or is suspected, such efforts seem well justified. This review will discuss recent progress in the development of drugs that inhibit NF-B activation, and consider their potential applications in inflammatory and autoimmune diseases, as well as cancer.

Author affiliations

1. Laboratory of Gene Regulation and Signal Transduction Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0636, USA.
2. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

Correspondence to: Michael Karin¹ Email: KarinOffice@ucsd.edu

Correspondence to: Q. May Wang² Email: qmwang@lilly.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.